IDEXX Laboratories (IDXX) Q1 FY26 earnings call: guidance and Q&A

Analyst expected more than 1,099 inVue Dx placements in Q1 given the 5,500 full-year target, asking about pacing dynamics and confidence in the full-year number.

Management expressed high confidence in the 5,500 full-year target, noting that Q1 placements can be choppy due to customer mix but market receptivity is strong.

“Keep in mind, we came off a very strong year in 2025 and Q4. We have a high degree of confidence in the 5,500 number. It tends to be -- you get some choppiness quarter-to-quarter, just based on customer mix of independents versus corporates.”

asked by Michael Ryskin · answered by Jay Mazelsky

Asked for more detail on the "modestly improved industry outlook" given the 1% visit decline in Q1.

Q1 clinical visits were 1% better than initial guide. Positive momentum from aging pets (5+ years old) for the third sequential quarter, across both well and non-well visits. Full-year clinical visit decline estimate is -1.5%, with strong diagnostic frequency and utilization per visit offsetting visit declines.

“We continue to see positive momentum from the aging pet population, pets that are 5-plus years and older continue to add some positive momentum just to the overall industry.”

asked by Michael Ryskin · answered by Andrew Emerson

Inquired about the drivers of strong ex-U.S. growth (commercial execution vs. market trends) and the sustainability. Also asked for more detail on F&A utilization and broader rollout plans.

International growth is driven by long-term investments in commercial expansion, Reference Lab build-out, localized software, and tailored product solutions. Diagnostics utilization is at an earlier stage internationally, offering significant runway. F&A controlled launch is on track, broadening in Q2, with an unconstrained launch later this year. Utilization is good, and the platform has significant future expansion potential.

“The really solid growth we're seeing in CAG recurring revenue, instrument placements internationally is a function of long-term investments that, as a company, we've made.”

asked by Christopher Schott · answered by Jay Mazelsky

Asked how much inVue Dx consumables are moving the needle versus IDEXX 360 contracts, and when inVue Dx consumables will have a more significant impact.

inVue Dx consumables (ear cytology, blood morphology) are definitely contributing to strong VetLab consumables growth and are within expectations, representing 100% new growth. The broad installed base of premium instruments allows rapid uptake of new menu items like Catalyst pancreatic lipase and cortisol, driving overall consumables growth.

“The inVue consumables is definitely contributing to the strong growth and momentum we see in the VetLab consumables portfolio with ear cytology, blood morphology... It represents 100% new growth in the consumables area that we didn't have before.”

asked by Erin Wilson Wright · answered by Jay Mazelsky

Questioned how CAG Dx recurring revenue growth could accelerate in H2 given Q1/Q2 guidance implies ~10.25% for H1, while full-year midpoint is 9.7%, and clinical visits are not expected to improve.

The increased full-year outlook (70 bps at midpoint) is driven by continued global execution, strong benefits from new innovations (inVue Dx, Catalyst menu), expanded utilization, and a modest improvement in clinical visit outlook. Reference Lab momentum and the innovation agenda (Cancer Dx expansion, F&A full volume ramp) also contribute to confidence in sustaining momentum.

“The business just has a lot of momentum because of that. And we've been, I think, transparent with customers in terms of the innovation agenda around what's coming, the expansion of IDEXX cancer diagnostics as an example, continued to build into more of a full volume posture with inVue Dx F&A in the second half of the year.”

asked by Jonathan Block · answered by Jay Mazelsky

Asked if IDEXX is already within the previously communicated "$3,500 to $5,500 revenue per box" range for inVue Dx and if the full F&A launch is needed to reach it.

Management confirmed they are "well within the range" of recurring revenue per instrument, even before the unconstrained F&A launch. They expect F&A to provide further opportunity, given the large addressable market for fine needle aspirates.

“We're well within the range that we've communicated. We're happy with that. And that's really before moving to an unconstrained launch position with F&A. So we see more opportunity ahead.”

asked by Jonathan Block · answered by Andrew Emerson

Asked about assumptions regarding macro/fuel prices in the updated visit guide and if there were changes in visit/diagnostic frequency trends between January, February, and March due to fuel price increases.

Fuel prices are a dynamic factor, but the visit guide is calibrated to recent trends. Wellness and discretionary categories are the primary drivers of declines. Non-well visits have been relatively flat, indicating prioritization of essential care. Monthly visit dynamics are too noisy to break out, but Q1's -1% decline was consistent with expectations for wellness pressure and better non-well performance.

“We don't typically break out the monthly dynamics just relative to visits. It can be really noisy. There's a lot of factors including things like day accounts, et cetera, that can play out in a month.”

asked by Daniel Christopher Clark · answered by Andrew Emerson

Inquired about the underlying reasons for the positive trend in non-wellness visits, specifically if it relates to the aging pet population or pent-up demand.

The positive trend is linked to the aging pet population, particularly the 5- to 7-year cohort adopted during the pandemic. These pets are often breeds that require more medical care (e.g., doodles, frenchies), suggesting a sustainable trend as this large cohort ages.

“We have seen it in that 5- to 7-year cohort. So these are pet adoptions that largely occurred during the pandemic, where we had that huge step up. And what we've seen in terms of the type of breeds that were adopted during the pandemic is they're more heavily medicalized.”

asked by Ryan Daniels · answered by Jay Mazelsky